Literature DB >> 22551808

Effectiveness of 1 dose of 2009 influenza A (H1N1) vaccine at preventing hospitalization with pandemic H1N1 influenza in children aged 7 months-9 years.

James L Hadler1, Tai N Baker, Vikki Papadouka, Anne Marie France, Christopher Zimmerman, Kara A Livingston, Jane R Zucker.   

Abstract

The availability of a well-established immunization registry to provide vaccination information, a school-located vaccination campaign followed by continued 2009 influenza A (H1N1) (pH1N1) activity, and a requirement to report hospitalized influenza cases provided an opportunity to estimate vaccine effectiveness (VE) of an initial dose of pH1N1 monovalent vaccine in children aged 7 months-9 years. Seventy-eight case children and 729 date-of-birth- and zipcode-matched controls were studied. The VE of a single vaccine dose in preventing pH1N1 hospitalization ≥ 14 days after vaccination was 82% (95% confidence interval [CI], 0%-100%; P = .04) in children aged 3-9 years but was zero (-3%; 95% CI, <0%-75%) in children aged 7-35 months. These findings are consistent with those from prelicensure immunogenicity studies and have implications for interpretation of immunogenicity studies and setting priorities for vaccination of young children in future pandemics. Immunization registries can provide a simple, rapid assessment of VE to evaluate and inform vaccination policy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22551808     DOI: 10.1093/infdis/jis306

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Evaluation of the frequency of immunization information system use for public health research.

Authors:  Eileen A Curran; Robert A Bednarczyk; Saad B Omer
Journal:  Hum Vaccin Immunother       Date:  2013-02-19       Impact factor: 3.452

Review 2.  Perspectives from the Society for Pediatric Research: Decreased Effectiveness of the Live Attenuated Influenza Vaccine.

Authors:  Michelle A Gill; Elizabeth P Schlaudecker
Journal:  Pediatr Res       Date:  2017-11-08       Impact factor: 3.756

3.  Evaluation of a New Clinical Endpoint for Moderate to Severe Influenza Disease in Children: A Prospective Cohort Study.

Authors:  Suchitra Rao; Emad Yanni; Angela Moss; Molly M Lamb; Anne Schuind; Rafik Bekkat-Berkani; Bruce L Innis; Jillian Cotter; Rakesh D Mistry; Edwin J Asturias
Journal:  J Pediatric Infect Dis Soc       Date:  2020-09-17       Impact factor: 3.164

4.  [Health Technology Assessment (HTA) of the introduction of influenza vaccination for Italian children with Fluenz Tetra®].

Authors:  Sara Boccalini; Elena Pariani; Giovanna Elisa Calabrò; Chiara DE Waure; Donatella Panatto; Daniela Amicizia; Piero Luigi Lai; Caterina Rizzo; Emanuele Amodio; Francesco Vitale; Alessandra Casuccio; Maria Luisa DI Pietro; Cristina Galli; Laura Bubba; Laura Pellegrinelli; Leonardo Villani; Floriana D'Ambrosio; Marta Caminiti; Elisa Lorenzini; Paola Fioretti; Rosanna Tindara Micale; Davide Frumento; Elisa Cantova; Flavio Parente; Giacomo Trento; Sara Sottile; Andrea Pugliese; Massimiliano Alberto Biamonte; Duccio Giorgetti; Marco Menicacci; Antonio D'Anna; Claudia Ammoscato; Emanuele LA Gatta; Angela Bechini; Paolo Bonanni
Journal:  J Prev Med Hyg       Date:  2021-09-10

5.  Agreement among sources of adult influenza vaccination in the age of immunization information systems.

Authors:  Mary Patricia Nowalk; Helen Eleni Aslanidou D'Agostino; Richard K Zimmerman; Sean G Saul; Michael Susick; Jonathan M Raviotta; Theresa M Sax; G K Balasubramani
Journal:  Vaccine       Date:  2021-10-27       Impact factor: 3.641

6.  Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine.

Authors:  Jessie R Chung; Brendan Flannery; Mark G Thompson; Manjusha Gaglani; Michael L Jackson; Arnold S Monto; Mary Patricia Nowalk; H Keipp Talbot; John J Treanor; Edward A Belongia; Kempapura Murthy; Lisa A Jackson; Joshua G Petrie; Richard K Zimmerman; Marie R Griffin; Huong Q McLean; Alicia M Fry
Journal:  Pediatrics       Date:  2016-01-05       Impact factor: 7.124

7.  Effectiveness of monovalent and pentavalent rotavirus vaccine.

Authors:  Margaret M Cortese; Lilly Cheng Immergluck; Melissa Held; Shabnam Jain; Trisha Chan; Alexandra P Grizas; Saadia Khizer; Carol Barrett; Osbourne Quaye; Slavica Mijatovic-Rustempasic; Rashi Gautam; Michael D Bowen; Jessica Moore; Jacqueline E Tate; Umesh D Parashar; Marietta Vázquez
Journal:  Pediatrics       Date:  2013-06-17       Impact factor: 7.124

8.  The parasite-derived rOv-ASP-1 is an effective antigen-sparing CD4+ T cell-dependent adjuvant for the trivalent inactivated influenza vaccine, and functions in the absence of MyD88 pathway.

Authors:  Sonia Jain; Parakkal Jovvian George; Wanyan Deng; Joseph Koussa; Kaela Parkhouse; Scott E Hensley; Jiu Jiang; Jie Lu; Zhuyun Liu; Junfei Wei; Bin Zhan; Maria Elena Bottazzi; Hao Shen; Sara Lustigman
Journal:  Vaccine       Date:  2018-06-14       Impact factor: 3.641

9.  Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.

Authors:  Karen L Kotloff; Natasha B Halasa; Christopher J Harrison; Janet A Englund; Emmanuel B Walter; James C King; C Buddy Creech; Sara A Healy; Rowena J Dolor; Ina Stephens; Kathryn M Edwards; Diana L Noah; Heather Hill; Mark Wolff
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129

10.  Did the H1N1 Vaccine Reduce the Risk of Admission with Influenza and Pneumonia during the Pandemic?

Authors:  Salaheddin M Mahmud; Songul Bozat-Emre; Gregory Hammond; Lawrence Elliott; Paul Van Caeseele
Journal:  PLoS One       Date:  2015-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.